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Phosphorylase kinase is a multimeric protein kinase
(a4b4g4d4) whose enzymatic activity is conferred by its
g-subunit. A library of 18 overlapping synthetic peptides
spanning residues 277–386 of the g-subunit has been
prepared to use in identifying important regulatory
structures in the protein. In the present study, the li-
brary was screened to identify regions that might func-
tion as autoinhibitory domains. Peptides from two dis-
tinct regions were found to inhibit the Ca21-activated
holoenzyme. The same regions were previously found to
bind calmodulin (i.e. the d-subunit; Dasgupta, M. Honey-
cutt, T., and Blumenthal, D. K. (1989) J. Biol. Chem. 264,
17156–17163). Themost potent substrate antagonist pep-
tides were PhK13 (residues 302–326; Ki 5 300 nM) and
PhK5 (residues 342–366; Ki 5 20 mM). Both peptides in-
hibited the holoenzyme competitively with respect to
phosphorylase b and noncompetitively with respect to
MgzATP. When the pattern of inhibition with both pep-
tides present was analyzed, inhibition was observed to
be synergistic and modestly cooperative indicating that
the two peptides can simultaneously occupy the protein
substrate-binding site(s). These data are consistent with
a model in which the regions of the g-subunit repre-
sented by PhK5 and PhK13 work in concert as regula-
tory subdomains that transduce Ca21-induced confor-
mational changes in the d-subunit to the catalytic
g-subunit through a pseudosubstrate autoinhibitory
mechanism.
Phosphorylase kinase is among the largest and most complex
of the protein kinase superfamily (reviewed by Pickett-Gies
and Walsh (1)). Because of its complex structure, the catalytic
activity of phosphorylase kinase is sensitive to a variety of
effectors and chemical modifications including pH, divalent
metal ions, ionic strength and composition, glycogen, calmod-
ulin, nucleosides, phosphorylation state, limited proteolysis,
and substrate conformation. The subunit composition of phos-
phorylase kinase is a4b4g4d4, where the a-, b-, and d-subunits
are regulatory and the g-subunit harbors the catalytic site. The
a- and b-subunits can be phosphorylated, and this modification
increases the enzyme’s catalytic activity, whereas the d-sub-
unit is identical to calmodulin and confers Ca21 dependence to
the enzyme’s activity. Although the a-, b-, and d-subunits are
all thought to interact directly with the g-subunit, the molec-
ular mechanisms by which these regulatory subunits effect
changes in catalytic activity is not well understood at present.
A common mechanism by which the catalytic activity of
many protein kinases appears to be regulated is through a
pseudosubstrate autoinhibitory mechanism (see reviews by
Soderling (2) and Kemp and Pearson (3)). This intrasteric form
of regulation was first described in the cAMP-dependent pro-
tein kinase, but there is now substantial evidence that this
mechanism may also be operating in the cGMP-dependent
protein kinases, myosin light chain kinases, calmodulin-de-
pendent type II kinases, the protein kinase-Cs, as well as the
protein phosphatase calcineurin (2, 3). The simplest mechanis-
tic model for this form of regulation consists of two conforma-
tional states: an autoinhibited enzymatically inactive (or less
active) state and a deinhibited active (or more active) state. In
the autoinhibited state, an autoinhibitory regulatory domain
occupies the enzyme’s substrate-binding site and prevents ac-
cess of the protein substrate to the catalytic site. Upon binding
of an allosteric activator to the regulatory domain, a conforma-
tional change is induced in the autoinhibitory domain that
removes it from the substrate-binding site allowing free access
of the substrate to the catalytic site.
Typically, the amino acid sequence of an autoinhibitory do-
main closely resembles the consensus sequence of that en-
zyme’s preferred substrates and is then termed a pseudosub-
strate domain. In a number of cases, protein kinase
pseudosubstrate domains also contain phosphorylatable resi-
dues, and these residues can be autophosphorylated. Thus,
identification of putative pseudosubstrate autoinhibitory do-
mains often entails visual inspection of a protein kinase’s reg-
ulatory domain for sequences that resemble consensus sub-
strate sequences. Candidate pseudosubstrate sequences are
then chemically synthesized and tested for their ability to
inhibit the enzyme in question. Although the peptide repre-
senting an enzyme’s pseudosubstrate domain should act as a
competitive inhibitor of the protein (or peptide) substrate, this
is not always the case (2, 3). Moreover, it is conceivable that
selecting a putative pseudosubstrate domain on the basis of
similarity to a substrate consensus sequence could result in a
false positive identification, particularly if the inhibitory capac-
ity of the putative synthetic pseudosubstrate is low. Thus,
positive identification of putative pseudosubstrate domains
must be supported by other data including site-directed mu-
tagenesis and x-ray crystallographic structures.
The present investigation is the second phase of a long term
effort to characterize the structure-function relationships of the
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regulatory domain of the g-subunit of phosphorylase kinase.
The regulatory domain of the g-subunit is defined here as the
region spanning amino acids 277–386 of this subunit. The first
phase of this investigative effort involved identification of pu-
tative d-subunit-binding domains in the regulatory domain by
preparing a library of 18 overlapping synthetic peptides span-
ning residues 277–386 and screening each peptide for its ability
to bind calmodulin (4). Two noncontiguous peptides were iden-
tified as being likely d-subunit-binding domains. In the present
study, the same synthetic peptide library has been used to
screen for possible g-subunit autoinhibitory domains. Two non-
contiguous regions in the g-subunit regulatory domain have
been identified that display the properties expected of
pseudosubstrate autoinhibitory domains. These results are be-
ing used to direct structural studies to further elucidate the
molecular mechanisms underlying the regulation of phospho-
rylase kinase catalytic activity.
EXPERIMENTAL PROCEDURES
Synthetic Peptides—A series of 18 overlapping 25-residue peptides
corresponding to the C-terminal 110 residues (277–386) of the g-sub-
unit of phosphorylase kinase was synthesized and characterized as
described by Dasgupta et al. (4). Each peptide was assigned a number
based on its position relative to the C terminus of the g-subunit of
phosphorylase kinase (4). The nomenclature and sequence of each pep-
tide are shown in Table I. Shorter analogs of both PhK13 and PhK6
were synthesized as described in Blumenthal and Krebs (5). The no-
menclature and sequence of these peptides is described in Table II. All
of the peptides in Tables I and II were synthesized with glycine-amide
C termini. The composition and sequence of every synthetic peptide was
confirmed by quantitative amino acid analysis using a Beckman model
6800 amino acid analyzer following acid hydrolysis and by sequence
analysis using an Applied Biosystems Protein Sequencer model 477A.
Protein Preparation—Phosphorylase kinase was purified from rabbit
skeletal muscle according to Cohen (12), and phosphorylase b was
prepared according to Krebs and Fisher (6). Rabbit skeletal muscle
myosin light chain kinase was purified as described by Takio et al. (7).
Calmodulin was prepared from bovine testis by using the following
sequence of steps: batchwise chromatography using DEAE-cellulose
(DE52, Whatman Ltd.), Ca21-dependent interaction chromatography
(8) using phenyl-Sepharose (Sigma), and gel filtration chromatography
(Bio-Gel A-0.5m, Bio-Rad).
Phosphorylase Kinase Assay—The rate of incorporation of 32P into
glycogen phosphorylase b was used to measure phosphorylase kinase
activity. The final reaction mixtures (50 ml) for the inhibition experi-
ments contained 50 mM Tris, 50 mM b-glycerol phosphate, pH 8.2, 1 mM
dithiothreitol, 30 mM phosphorylase b, 10 mM magnesium acetate, 100
mM calcium chloride, 1 mM [g-32P]ATP ('300 counts/min/pmol; DuPont
NEN), 1 mg/ml nonactivated phosphorylase kinase, and varying concen-
trations of synthetic g-subunit peptides as indicated in the figure leg-
ends. Reactions were performed in duplicate at 30 °C, and 20-ml sam-
ples of each reaction were spotted on Whatman 3MM filter paper
squares (1 3 1 cm) at 5 and 15 min. The squares were immediately
immersed in 10% trichloroacetic acid, 4% sodium pyrophosphate and
processed as described by Corbin and Reimann (9). All rates of phos-
phorylation were linear with respect to time for at least 15 min.
Calmodulin-binding Assay—Calmodulin-binding activity was quan-
titated using a myosin light chain kinase inhibition assay as described
previously (4). The reaction mixtures (50 ml final volume) for peptide
inhibition experiments contained 50 mM MOPS,1 pH 7.0, 1 mM dithio-
threitol, 130 mM substrate peptide (KKRPQRATSNVFS-amide), 10 mM
magnesium acetate, 0.2 mM calcium chloride, 10 nM calmodulin, 1.3 nM
skeletal muscle myosin light chain kinase, 1 mM [g-32P]ATP ('300
counts/min/pmol; DuPont NEN), and varying concentrations of syn-
thetic g-subunit peptides as indicated. Reactions were performed in
duplicate at 30 °C, and 20-ml samples of the reaction were spotted on
Whatman P81 phosphocellulose filter paper squares (1 3 1 cm) at 5 and
15 min. The squares were immediately immersed in 75 mM phosphoric
acid and processed as described by Roskoski (10). All rates of 32P
incorporation were linear with respect to time for at least 15 min.
Protein Estimation—The concentration of myosin light chain kinase
was determined by the method of Bradford (11), using bovine serum
albumin as a standard. Other protein concentrations were determined
spectrophotometrically using values of E280 nm,1% of 12.4 for phospho-
rylase kinase (12) and 13.2 for phosphorylase b (13), respectively, and a
value of E276 nm,1% of 1.8 for calmodulin (14). Concentrations of phos-
phorylase b are expressed in terms of molar concentrations of monomer.
Kinetic Analysis—The Ki values of the peptides that inhibited phos-
phorylase kinase activity were determined using the following equation
for competitive inhibition (15):
i 5 1 2
vi
v0
5
@I#
@I# 1 KiS1 1 @S#KmD
(Eq. 1)
where i is the fractional inhibition observed in the presence of peptide
inhibitor, [I] is the concentration of peptide inhibitor, [S] is the concen-
tration of phosphorylase b (30 mM) used in the reaction mixture, Km is
the Michaelis constant for phosphorylase b (33 mM), and vi and v0 are
the reaction rates in the presence and absence of peptide inhibitor,
respectively. Ki values were determined by Marquardt weighted non-
linear least-squares fit estimation using the MathView Professional
(v 1.2) program run on a Macintosh computer. The assumption of
competitive inhibition used in these calculations was validated by ki-
netic analysis (see “Results”).
RESULTS
The purpose of the present investigation was to determine
the possible location of autoinhibitory domain(s) within the C
terminus of the g-subunit. The approach taken was analogous
to that previously used to identify d-subunit (integral calmod-
ulin)-binding domains in the g-subunit. This approach utilizes
a library of eighteen overlapping 25-residue synthetic peptides
(the sequences and nomenclature are shown in Table I) based
on the C-terminal 110 residues of the g-subunit. The library
was constructed in such a way that every 20-residue segment
between residue 277 and the C terminus (residue 386) of the
g-subunit is represented in one of the 18 peptides. Each peptide
in the library was assayed for its ability to inhibit the catalytic
activity of nonactivated (nonphosphorylated) phosphorylase ki-
nase holoenzyme. The assay reaction was performed at pH 8.2
in the presence of Ca21 with limiting concentrations of the
substrate, phosphorylase b. Under these conditions, a peptide
that can compete with phosphorylase b for the substrate-bind-
ing site of the enzyme will inhibit enzyme activity. The results
of the assay are depicted in Table I, where the Ki value of each
peptide is compared with its previously determined KD for
calmodulin (4). The Ki value of each peptide was calculated as
described under “Experimental Procedures.” Peptides that
showed no appreciable inhibition of phosphorylase kinase ac-
tivity at a concentration of 50 mM are indicated as having Ki
values .100,000 mM.
The data in Table I indicate that the g-subunit regulatory
domain peptides which exhibit the most potent inhibitory ac-
tivity are located in two distinct regions that closely correspond
to the regions previously shown to be involved in d-subunit
interactions (4). Moreover, the peptides from each region that
most strongly inhibited phosphorylase kinase activity, PhK5
and PhK13 (Ki values of 20 mM and 300 nM, respectively), are
the same peptides from each region that were previously found
to bind calmodulin with the highest affinity (KD values of 20
and 6.5 nM, respectively (4)). The Ki values estimated for PhK5
and PhK13 are both within the range of values reported for
autoinhibitory domain peptides from other protein kinases (40
nM to 25 mM; see reviews by Soderling (2) and Kemp and
Pearson (3)).
To determine the mechanism(s) by which PhK5 and PhK13
inhibit the catalytic activity of phosphorylase kinase, the ki-
netics of inhibition for each peptide were analyzed as a function
of phosphorylase b and ATP concentration. The data obtained
with PhK13 and PhK5 are plotted in Fig. 1. Fig. 1A shows
double-reciprocal plots of phosphorylation rates as a function of1 The abbreviation used is: MOPS, 4-morpholinepropanesulfonic acid.
Bifunctional Regulatory Subdomains of Phosphorylase Kinase22284
 by guest on February 1, 2018
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
phosphorylase b concentration obtained when nonactivated
phosphorylase kinase was assayed in the presence of Ca21 (100
mM), a fixed concentration of ATP (1 mM), and various fixed
concentrations of PhK13 (0.3–3 mM). The intersection of the
double-reciprocal plots for the various concentrations of PhK13
on the (1/v)-axis at [phosphorylase b]21 5 0 indicates that
FIG. 1. Double-reciprocal plots of phosphorylase kinase inhibition by PhK5 and PhK13. Panels A and B show double-reciprocal plots
of phosphorylase kinase inhibition by the indicated concentrations of PhK13 as a function of phosphorylase b and ATP concentration, respectively.
Panels C andD show the corresponding plots for inhibition by PhK5. The concentration of ATP used in panels A and Cwas 1 mM. The concentration
of phosphorylase b used in panels B and D was 30 mM. Other details of the reaction conditions are given under “Experimental Procedures.”
TABLE I
Inhibition of phosphorylase kinase activity by g-subunit regulatory domain peptides
The nomenclature, residue range, sequence, and Ki value for each synthetic peptide are shown. The Ki values were estimated by non-linear
curve-fitting as described under “Experimental Procedures.” Dissociation constants for calmodulin binding are also indicated for each peptide (4).
Name Residues Sequence Calmodulinbinding
Substrate
antagonism
KD, nM Ki, nM
PhK1 362–386 QQQNRAALFENTPKAVLFSLAEDDY (.50,000) (.100,000)
PhK2 357–381 WVKKGQQQNRAALFENTPKAVLFSL 4,700 (.100,000)
PhK3 352–376 RIYGHWVKKGQQQNRAALFENTPKA 794 (.100,000)
PhK4 347–371 DAYAFRIYGHWVKKGQQQNRAALFE 190 50,000
PhK5 342–366 LRRLIDAYAFRIYGHWVKKGQQQNR 20 20,000
PhK6 337–361 YALRPLRRLIDAYAFRIYGHWVKKG 36 33,000
PhK7 332–356 VIRDPYALRPLRRLIDAYAFRIYGH 430 (.100,000)
PhK8 327–351 VTREIVIRDPYALRPLRRLIDAYAF (.50,000) (.100,000)
PhK9 322–346 RRVKPVTREIVIRDPYALRPLRRLI (.50,000) (.100,000)
PhK10 317–341 IYYQYRRVKPVTREIVIRDPYALRP (.50,000) (.100,000)
PhK11 312–336 LASVRIYYQYRRVKPVTREIVIRDP (.50,000) (.100,000)
PhK12 307–331 ICLTVLASVRIYYQYRRVKPVTREI 14 2,000
PhK13 302–326 GKFKVICLTVLASVRIYYQYRRVKP 6.5 300
PhK14 297–321 HFSPRGKFKVICLTVLASVRIYYQY 35 2,000
PhK15 292–316 VEEVRHFSPRGKFKVICLTVLASVR 56 2,000
PhK16 287–311 FQQYVVEEVRHFSPRGKFKVICLTV 640 10,000
PhK17 282–306 LAHPFFQQYVVEEVRHFSPRGKFKV (.50,000) (.100,000)
PhK18 277–301 TAEEALAHPFFQQYVVEEVRHFSPR (.50,000) (.100,000)
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PhK13 acts as a competitive inhibitor of phosphorylase b. A
replot of the slopes in Fig. 1A as a function of PhK13 concen-
tration (shown in Fig. 2A) yields an estimate of 300 nM for the
value of the Ki, the same value as estimated by non-linear
curve-fitting procedures (Table I). Double-reciprocal plots of
phosphorylase kinase activity as a function of ATP concentra-
tion, at various fixed concentrations of PhK13, and at a fixed
concentration of phosphorylase b (30 mM) are shown in Fig. 1B.
In this case, the double-reciprocal plots intersect on the
[ATP]21-axis indicating that PhK13 acts as a pure noncompet-
itive inhibitor with respect to ATP (15).
The double-reciprocal plots shown in Fig. 1 indicate that the
peptide PhK5 inhibits the catalytic activity of phosphorylase
kinase in a manner similar to PhK13. Fig. 1C shows a series of
plots in double-reciprocal format where the x axis represents
the reciprocal of the concentration of phosphorylase b, the y
axis represents the reciprocal of the reaction rate, and each line
represents data obtained at the indicated concentration of
PhK5. As in the case of PhK13, the lines converge on the y axis
at [phosphorylase b]21 5 0, indicating competitive inhibition
by PhK5 with respect to phosphorylase b. A replot of the slopes
of the lines in Fig. 1C as a function of PhK5 concentration (Fig.
2B) yields a Ki value for PhK5 of 20 mM, the same value
obtained by non-linear curve-fitting procedures (Table I). The
double-reciprocal plots shown in Fig. 1D, where the rate of
phosphorylase kinase activity is plotted as a function of ATP
concentration at various fixed concentrations of PhK5, indicate
that PhK5 exhibits hyperbolic (partial) mixed-type inhibition
with respect to ATP (15). A hyperbolic mixed-type inhibition
pattern indicates that PhK5 causes a change in theKm for ATP,
as well as a change in the Vmax, and is thus acting as a partial
noncompetitive inhibitor. Intersection of the double-reciprocal
plots below the x axis (1/[ATP]) indicates that PhK5 causes a
decrease in the Km for ATP (15). Secondary replots (not shown)
of the reciprocal of the y axis intercept (1/D intercept) as a
function of the reciprocal of PhK5 concentration indicate that
binding of PhK5 to phosphorylase kinase decreases the Km for
ATP by about 2-fold (a 5 0.47) and reduces Vmax by about 5-fold
(b 5 0.18). A pure noncompetitive inhibitor would have no
effect on Km (a 5 1) and would totally block catalysis when
bound to the enzyme (b 5 0).
Thus, PhK5 and PhK13 both act as competitive inhibitors of
phosphorylase b, and both are noncompetitive inhibitors of
ATP, although unlike PhK13, PhK5 is not a pure noncompet-
itive inhibitor of ATP. The pattern of inhibition seen with PhK5
and PhK13 is consistent with the phosphorylation reaction
mechanism being a sequential rapid-equilibrium random Bi-Bi
mechanism, as previously reported (16–18). The pattern of
inhibition seen here is similar to what was reported using
synthetic peptides based on the putative autoinhibitory domain
of skeletal muscle myosin light chain kinase, an enzyme that
also exhibits a rapid-equilibrium random Bi-Bi mechanism (19,
20). Those peptides inhibited myosin light chain kinase com-
petitively with respect to phosphate acceptor substrate and
noncompetitively with respect to ATP (21). As in the case of
myosin light chain kinase (21), addition of a molar equivalent
of calmodulin relative to inhibitor peptide was able to overcome
inhibition (data not shown).
The finding that both PhK5 and PhK13 are competitive
inhibitors of phosphorylase b phosphorylation raises the ques-
tion as to whether the peptides can act synergistically or
whether their inhibition is mutually exclusive. To answer this
question, the activity of phosphorylase kinase inhibited by
mixtures of PhK5 and PhK13 was analyzed graphically using
Dixon plots, as shown in Fig. 3. In Fig. 3A, the reciprocal of the
reaction rate is plotted as a function of PhK13 concentration at
various fixed concentrations of PhK5. The same data are shown
in Fig. 3B, but in this plot the reciprocal of the reaction rate is
plotted as a function of PhK5 concentration, with each line
representing a different concentration of PhK13. In Fig. 3, A
and B, the lines converge indicating that inhibition by PhK5
and PhK13 with respect to phosphorylase b is synergistic (15).
Parallel lines would have indicated that the two peptides in-
hibited the enzyme in a mutually exclusive manner. The point
at which the lines converge in each plot provides information
regarding the degree of cooperativity between the two inhibi-
tors. The x axis value where the lines converge is equal to2aKi,
where Ki is the inhibition constant for the inhibitor that was
varied and a is the coefficient of cooperativity. When a 5 1, it
indicates a lack of cooperativity between the inhibitors. When
a . 1, it indicates that inhibitor binding is negatively cooper-
ative, whereas when a , 1, it indicates that inhibitor binding is
positively cooperative. The values of a calculated from Fig. 3, A
and B, were 0.35 and 0.67, respectively, based on the previously
determined Ki values for PhK13 and PhK5 (0.3 and 20 mM,
respectively; cf. Table I and Fig. 2). These two estimates for a
are in reasonable agreement with each other and indicate that
the simultaneous binding of PhK5 and PhK13 to the phospho-
rylase b substrate-binding site shows modest positive cooper-
ativity (0.3 # a # 0.7). These values indicate that the binding
of one peptide to the enzyme enhances the binding of the other
peptide by about a factor of 2. Synergistic inhibition between
PhK5 and PhK13 also indicates that phosphorylase kinase
contains a distinct binding site for each peptide. Taken to-
gether with the data that both peptides are competitive inhib-
FIG. 2. Determination of Ki values for PhK13 and PhK5 from
replots of slope versus peptide concentration. Slopes of lines de-
termined from plots shown in Fig. 1, A and C, were replotted as a
function of PhK13 and PhK5 concentration, respectively, to determine
Ki values for PhK5 and PhK13 with respect to phosphorylase b.
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itors of phosphorylase b suggests that phosphorylase kinase
may have two distinct binding sites for phosphorylase b.
To better define the determinants in PhK5 and PhK13 crit-
ical for autoinhibitory function versus d-subunit interaction, a
series of truncated peptides was prepared and assayed for
phosphorylase kinase inhibitory activity and calmodulin bind-
ing activity. Because standard solid-phase peptide synthesis
proceeds from the carboxyl terminus toward the amino termi-
nus of the peptide, a series of truncation peptides which share
a common carboxyl terminus can be easily prepared by remov-
ing aliquots of peptide resin at different stages during the
synthesis. Table II shows the sequences, calmodulin-binding
affinity, estimated Ki for autoinhibition, and nomenclature for
the eight peptides that were synthesized. The sequences of
PhK5, PhK6, and PhK13 and their respective data are also
presented in Table II for purposes of comparison.
Because PhK5 and PhK6 exhibit similar Ki values for auto-
inhibition and similar affinities for calmodulin, it is reasonable
to propose that the minimum essential determinants for auto-
inhibition and d-subunit binding function for this regulatory
subdomain would be contained in the sequence common to both
peptides. This core sequence is represented by the peptide
termed PhK6E which has the same amino terminus as PhK5
and the same carboxyl terminus as PhK6, but which lacks the
carboxyl-terminal sequence of PhK5 (Gln-Gln-Gln-Asn-Arg)
and the amino-terminal sequence of PhK6 (Tyr-Ala-Leu-Arg-
Pro). TheKi value for autoinhibition with PhK6E is the same as
that for PhK6 and approximately 50% higher than for PhK5,
suggesting that the sequence Tyr-Ala-Leu-Arg-Pro (337–341)
does not contain determinants essential for autoinhibition,
whereas determinants in the sequence Gln-Gln-Gln-Asn-Arg
(362–366) contribute modestly to the Ki value. With regard to
its affinity for calmodulin, PhK6E binds calmodulin 5-fold
weaker than PhK6 and 10-fold weaker than PhK5, suggesting
that the sequences Tyr-Ala-Leu-Arg-Pro (337–341) and Gln-
Gln-Gln-Asn-Arg (362–366) both contribute significantly to the
interactions of the g-subunit with the d-subunit. The peptide
PhK6D, which is two residues shorter at its amino terminus
than PhK6E, had a Ki value for autoinhibition that was only
about 30% greater than PhK6E, but bound calmodulin about
8-fold weaker, indicating that Leu-Arg (342–343) contributes
significantly to d-subunit binding, but is only marginally im-
portant for autoinhibition. Similar effects on affinity for cal-
modulin and Ki for autoinhibition were observed when the
sequence Arg-Leu-Ile (344–346) was removed on going from
PhK6D to PhK6C. The peptide PhK6B, which is three residues
shorter than PhK6C, has no detectable autoinhibitory activity
at concentrations as high as 50 mM, but still retains the ability
to bind calmodulin with low affinity (KD 5 20 mM). The peptide
PhK6A, which is two residues shorter than PhK6B, has no
detectable autoinhibitory activity or affinity for calmodulin.
Thus, it appears that the sequence represented by PhK5 is the
shortest sequence in the C-terminal regulatory domain of the
g-subunit with optimal autoinhibitory activity. The differences
in affinity for calmodulin observed between PhK6 and PhK6E
suggest that adding the sequence Tyr-Ala-Leu-Arg-Pro (337–
341) to the amino terminus of PhK5 to form a 30-residue
peptide (337–366) might increase the affinity for calmodulin
above that seen with PhK5, but this idea has not been tested.
The studies with peptides based on PhK13 included two
truncated peptides that were shorter than PhK13 and one
peptide that was one residue longer at its amino terminus than
PhK13 (Table II). The longer peptide PhK13C (301–326) had
Arg301 added to its amino terminus and showed a 6.5-fold
higher affinity for calmodulin than PhK13 and a Ki for autoin-
hibition that was 33% lower than for PhK13. These data sug-
gest that this single Arg residue is important for both d-subunit
interactions and autoinhibition. Removing the six residue se-
quence Arg-Gly-Lys-Phe-Lys-Val (301–306) from the amino
terminus of PhK13 resulted in a 10-fold decrease in affinity for
calmodulin and less than a 2-fold increase in the Ki for auto-
inhibition relative to PhK13. Removing an additional five res-
idues, Ile-Cys-Leu-Thr-Val (307–311), resulted in a 15-residue
peptide (312–326) that had no detectable affinity for calmodu-
lin and no detectable autoinhibitory activity. These data sug-
gest that the sequence Ile-Cys-Leu-Thr-Val (307–311) is essen-
tial for both autoinhibition and d-subunit interactions.
Consistent with this proposal is the finding that all of the PhK
peptides that contain this sequence (PhK12 through PhK16)
have autoinhibitory and calmodulin binding activity, whereas
peptides immediately flanking these peptides are lacking in
both functional activities (Table I).
DISCUSSION
Using a library of overlapping synthetic peptides based on
the regulatory domain of the g-subunit of phosphorylase ki-
nase, two distinct noncontiguous regions, residues 302–326
(PhK13) and 342–356 (PhK5), have been identified as being
putative pseudosubstrate autoinhibitory domains. Peptides
from each of these two regions inhibited catalytic activity of
phosphorylase kinase competitively with respect to the phos-
FIG. 3. Inhibition of phosphorylase kinase activity by mix-
tures of PhK5 and PhK13. Phosphorylase kinase activity was deter-
mined at the indicated concentrations of PhK5 and PhK13 and repre-
sented in Dixon plots. Panel A depicts the effects on phosphorylase
kinase activity of fixed concentrations of PhK5 as a function of PhK13
concentration. The same data are replotted in panel B, but as a function
of PhK5 concentration at fixed concentrations of PhK13. The concen-
trations of phosphorylase b and ATP used in these reactions were 30 mM
and 1 mM, respectively. Other assay conditions are detailed under
“Experimental Procedures.”
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phate acceptor substrate, phosphorylase b, and noncompeti-
tively with respect to the phosphate donor substrate, MgzATP.
Moreover, peptides from the two regions inhibited catalytic
activity in a synergistic manner, indicating that both peptides
can bind the g-subunit at the same time. The inhibitory capac-
ity of these peptides could be overcome by the addition of a
molar excess of calmodulin, consistent with their previously
being identified as calmodulin(d-subunit)-binding domains (4).
This appears to be the first example of a calmodulin-regulated
protein kinase with multiple noncontiguous synergistic auto-
inhibitory/calmodulin-binding subdomains.
Reimann et al. (22) first suggested that the C-terminal 110
amino acids of the g-subunit (residues 277–386) might consti-
tute the regulatory domain of phosphorylase kinase. Subse-
quently, limited proteolysis (23) and genetically engineered
truncation mutants (24, 25) of the g-subunit were used to show
that residues 298–386 contain an autoinhibitory domain. The
two putative autoinhibitory domain sequences identified in the
present study, 302–326 (PhK13) and 342–356 (PhK5), are both
located in this region of the g-subunit. Neither of these se-
quences corresponds to the putative pseudosubstrate domain
proposed by Kemp and Pearson (3) who suggested that residues
332–353 might represent the pseudosubstrate domain based
upon inspection of the g-subunit sequence. Moreover, the pep-
tide containing this latter sequence, PhK7 (residues 332–356),
showed virtually no inhibitory activity in the present study
(Table I).
Because PhK5 and PhK13 act as competitive inhibitors of
phosphorylase b, some sequence similarity between these pep-
tides and phosphorylase might be expected. Sequence align-
ment of phosphorylase with PhK5 and PhK13 reveals that both
peptides contain short stretches of sequence that closely resem-
ble the sequence of phosphorylase (Fig. 4). The two regions of
highest sequence similarity correspond closely to the regions
required for substrate inhibitory activity based on the data
shown in Tables I and II. It is particularly noteworthy that a
major portion of PhK13 shows sequence similarity with the
sequence surrounding Ser14 in phosphorylase b, the phospho-
rylation site in phosphorylase b.
The most significant sequence similarity between PhK13
(Lys303 to Arg323) and phosphorylase b (Lys9 to Lys29) spans 21
amino acids. This sequence is only found in its entirety in
PhK13, the peptide with the lowest Ki value (0.3 mM) of the
inhibitory peptides in the region spanning PhK12 through
PhK16 (Table I). The sequence Ile-Cys-Leu-Thr-Val appears to
be especially important for inhibition because it is shared by all
of the inhibitory peptides in this group and because truncation
peptides based on PhK13 that lack this sequence are not in-
hibitory (Table II). Interestingly, the corresponding pentapep-
tide from phosphorylase b is a competitive inhibitor with a Ki
value of about 6 mM (26), and Ile-Ser-Val-Arg-Gly-Leu (phos-
phorylase b (13–18)) is the shortest synthetic peptide substrate
that can be phosphorylated by phosphorylase kinase (16).
Other important determinants of substrate recognition (26)
which are identical in the alignment of PhK13 and phospho-
rylase b include Lys9(Lys303), Lys11(Lys305), Ile13(Ile307), and
Leu18(Leu312). Using g-subunit(1–300), a truncated form of the
g-subunit that lacks a regulatory domain, Huang et al. (27)
recently demonstrated that Glu111 and Glu154 are involved in
binding peptide substrates at their P-3 and P-2 positions, re-
spectively. Mutations of these residues increased the Ki value
for PhK13 by 14- and 8-fold, respectively, indicating their in-
volvement in binding PhK13, as well as peptide substrates.
Thus, the sequence corresponding to PhK13 (residues 302–326)
appears to represent a prototypical pseudosubstrate domain
that regulates the catalytic activity of phosphorylase kinase by
preventing the phosphorylation site of phosphorylase b access
to the catalytic site.
The ability of PhK5 to act as a competitive inhibitor of
phosphorylase kinase holoenzyme (Fig. 1) and its sequence
similarity to a region of phosphorylase b approximately 50
residues C-terminal to Ser14 (Fig. 4) suggest that phosphoryl-
ase b may have a major binding site on the holoenzyme in
addition to the binding site that recognizes the sequence
around Ser14 and that this secondary binding site is also in-
volved in autoinhibition. The sequence in PhK5 showing the
FIG. 4. Amino acid sequence alignment of phosphorylase b(2–87), and putative phosphorylase kinase pseudosubstrate autoin-
hibitory domains from the g-subunit(296–377) and the b-subunit(296–377). Amino acid identities are indicated by (u), close chemical
similarities by (:), and distant similarities by (z). The sequences of PhK5 and PhK13 are underlined in bold and the interconvertible Ser14 of
phosphorylase b is underlined. The alignment of b-subunit(296–377) is taken from Sanchez and Carlson (32).
TABLE II
Effect of peptide length on calmodulin binding and inhibition of phosphorylase kinase activity by g-subunit regulatory domain peptides
The peptide name, residue range, sequence, and Ki value for each synthetic peptide are shown. The Ki values and calmodulin dissociation
constants were estimated by non-linear curve-fitting as described under “Experimental Procedures.”
Name Residues Sequence Calmodulinbinding
Substrate
antagonism
KD, nM Ki, nM
PhK5 342–366 LRRLIDAYAFRIYGHWVKKGQQNR 20 20,000
PhK6A 352–361 RIYGHWVKKG (.50,000) (.100,000)
PhK6B 350–361 AFRIYGHWVKKG 20,000 (.100,000)
PhK6C 347–361 DAYAFRIYGHWVKKG 10,000 45,000
PhK6D 344–361 RLIDAYAFRIYGHWVKKG 1,600 40,000
PhK6E 342–361 LRRLIDAYAFRIYGHWVKKG 200 30,000
PhK6 337–361 YALRPLRRLIDAYAFRIYGHWVKKG 36 33,000
PhK13 302–326 GKFKVICLTVLASVRIYYQYRRVKP 6.5 300
PhK13A 312–326 LASVRIYYQYRRVKP (.50,000) (.100,000)
PhK13B 307–326 ICLTVLASVRIYYQYRRVKP 75 500
PhK13C 301–326 RGKFKVICLTVLASVRIYYQYRRVKP 1 200
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highest similarity to phosphorylase is Arg-Ile-Tyr-Gly-His-Trp-
Val-Lys (residues 352–359) which aligns with His-Leu-Val-Gly-
Arg-Trp-Ile-Arg (residues 62–69) in phosphorylase (Fig. 4).
This sequence is shared by PhK4, PhK5, and PhK6, the only
inhibitory peptides in this region of the g-subunit (Table I). It is
interesting to note that Graves and co-workers have shown
that synthetic peptides corresponding to the sequence of phos-
phorylase b around its phosphorylation site are poor substrates
compared to the intact protein (26) and that longer a CNBr
fragment of phosphorylase b corresponding to residues 1–99
(16) exhibited a Km value intermediate between that of the
synthetic peptides and native phosphorylase b. The data ob-
tained in the present study showing that PhK5 inhibits phos-
phorylase kinase activity synergistically with PhK13 (Fig. 3)
provides further evidence that there are at least two distinct
substrate binding sites for phosphorylase b and that both of
these substrate binding sites might be used by autoinhibitory
elements in the g-subunit to regulate the catalytic activity of
phosphorylase kinase. Inspection of the several x-ray crystal
structures of phosphorylase (28, 29) show that the phosphoryl-
ation site and the PhK5-like region of phosphorylase are rela-
tively close to one another on the surface of the protein, adding
support to the idea that these two regions of phosphorylase
might be simultaneously involved in interactions with phos-
phorylase kinase.
The kinetics of inhibition seen with PhK5 and PhK13 in the
present study using phosphorylase kinase holoenzyme are in
basic agreement with studies done using a g-subunit trunca-
tion mutant, g-subunit(1–300), which represents a minimal
g-subunit catalytic subunit that lacks calmodulin-binding and
autoinhibitory pseudosubstrate domains (27). In the studies
with g-subunit(1–300), PhK5 and PhK13 were both found to be
potent inhibitors, although both PhK5 and PhK13 were slightly
less potent (3–6-fold) inhibitors of g-subunit(1–300) than the
holoenzyme. The patterns of inhibition of PhK5 and PhK13
toward g-subunit(1–300) were identical to those seen in the
present study using holoenzyme, except that PhK5 was a non-
competitive inhibitor with regard to phosphorylase b (as com-
pared to being a competitive inhibitor in the case of the holoen-
zyme) and a simple noncompetitive inhibitor with regard to
ATP (as compared to being a mixed noncompetitive inhibitor of
the holoenzyme). Because the g-subunit(1–300) represents a
minimal g-subunit catalytic subunit that lacks the many inter-
and intrasubunit interactions present in the holoenzyme, it is
not unexpected that some differences in potency and patterns
of inhibition might be observed for PhK5 and PhK13 between
the two forms of the enzyme.
In contrast to the findings of the present study, Newsholme
et al. (30) have concluded that neither PhK5 nor PhK13 are
likely to represent pseudosubstrate domains because both pep-
tides appeared to be noncompetitive inhibitors of phosphoryl-
ase b in their experiments. However, the kinetic data obtained
by these investigators for PhK13 could not conclusively dis-
criminate between competitive and noncompetitive inhibition
because of problems of solubility at high peptide concentra-
tions. No such solubility problems were encountered in the
experiments described here or in other studies involving rela-
tively high concentrations of PhK5 and PhK13 (27, 31). The
differences in results obtained cannot be readily explained but
might be due to differences in assay conditions or the quality of
peptides used in the two studies. PhK5 in particular has sev-
eral amino acids that are especially sensitive to incomplete side
chain deprotection and modification during synthesis, cleav-
age, and purification. All of the peptides used in the pres-
ent study were subjected to peptide sequence analysis, quanti-
tative amino acid analysis, and UV spectral analysis.
In addition to the two putative autoinhibitory domains in the
g-subunit, Sanchez and Carlson (32) have recently reported
that residues 420–436 in the b-subunit of phosphorylase ki-
nase may constitute a potential autoinhibitory domain. The
proposed sequence alignment relative to the phosphorylation
site in phosphorylase b is shown in Fig. 4. Kinetic analysis of a
synthetic peptide based on the b-subunit 420–436 sequence
indicated a pattern of inhibition that was competitive with
respect to phosphorylase b (Ki 5 921 mM) and uncompetitive
with respect to ATP using the d-g enzyme complex. How these
various autoinhibitory domains might interact in the holoen-
zyme remains to be answered. One possibility is that each
domain acts independently to inhibit phosphorylase b binding.
Another possibility is that the domain on the b-subunit acts by
inducing conformational changes in the regions corresponding
to PhK5 and PhK13, which in turn alter catalytic activity.
Elucidation of the precise mechanisms by which these various
autoinhibitory domains effect changes in the enzymatic activity
of phosphorylase kinase will require detailed structural studies
involving a variety of approaches including the use of syn-
thetic peptide analogs, site-directed mutagenesis, and x-ray
crystallography.
Acknowledgments—We are grateful to Dr. Mark A. L. Atkinson (The
University of Texas Health Center at Tyler) for performing the peptide
sequence analyses and to Dr. Barry Starcher (The University of Texas
Health Center at Tyler) for performing the peptide amino acid analyses.
We also wish to thank Theresa Honeycutt for her technical assistance
during the early phases of this work.
REFERENCES
1. Pickett-Gies, C. A., and Walsh, D. A. (1985) in The Enzymes (Boyer, P. D., and
Krebs, E. G., eds) pp. 395–459, Academic Press, New York
2. Soderling, T. R. (1990) J. Biol. Chem. 265, 1823–1826
3. Kemp, B. E., and Pearson, R. B. (1991) Biochim. Biophys. Acta 1094, 67–76
4. Dasgupta, M., Honeycutt, T., and Blumenthal, D. K. (1989) J. Biol. Chem. 264,
17156–17163
5. Blumenthal, D. K., and Krebs, E. G. (1987) Methods Enzymol. 139, 115–126
6. Krebs, E. G., and Fisher, E. H. (1956) Biochim. Biophys. Acta 20, 150–157
7. Takio, K., Blumenthal, D. K., Edelman, A. M., Walsh, K. A., Krebs, E. G., and
Titani, K. (1985) Biochemistry 24, 6028–6037
8. Gopalakrishna, R., and Anderson, W. B. (1982) Biochem. Biophys. Res.
Commun. 104, 830–836
9. Corbin, J. D., and Reimann, E. M. (1975) Methods Enzymol. 38, 287–290
10. Roskoski, R. (1983) Methods Enzymol. 99, 3–6
11. Bradford, M. M. (1976) Anal. Biochem. 72, 248–254
12. Cohen, P. (1973) Eur. J. Biochem. 34, 1–14
13. Kastenschmidt, L. L., Kastenschmidt, J., and Helmreich, E. (1968) Biochem-
istry 17, 3590–3608
14. Klee, C. B. (1977) Biochemistry 16, 1017–1024
15. Segel, I. H. (1974) Enzyme Kinetics, Wiley-Interscience, New York
16. Tabatabai, L. B., and Graves, D. J. (1978) J. Biol. Chem. 253, 2196–2202
17. Chan, K.-F. J., and Graves, D. J. (1982) J. Biol. Chem. 257, 5948–5955
18. Farrar, Y. J. K., and Carlson, G. M. (1991) Biochemistry 30, 10274–10279
19. Yazawa, M., and Yagi, K. (1978) J. Biochem. (Tokyo) 84, 1259–1265
20. Geuss, U., Mayr, G. W., and Heilmeyer, L. M. G. (1985) Eur. J. Biochem. 153,
327–334
21. Kennelly, P. J., Edelman, A. M., Blumenthal, D. K., and Krebs, E. G. (1987)
J. Biol. Chem. 262, 11958–11963
22. Reimann, E. M., Titani, K., Ericsson, L. H., Wade, R. H., Fischer, E. H., and
Walsh, K. A. (1984) Biochemistry 23, 4185–4192
23. Harris, W. R., Malencik, D. A., Johnson, C. M., Carr, S. A., Roberts, G. D.,
Byles, C. A., Anderson, S. R., Heilmeyer, L. M. G., Fischer, E. H., and
Crabb, J. W. (1990) J. Biol. Chem. 265, 11740–11745
24. Cox, S., and Johnson, L. N. (1992) Protein Eng. 5, 811–819
25. Huang, C.-Y. F., Yuan, C.-J., Livanova, N. B., and Graves, D. J. (1993) Mol.
Cell. Biochem. 127/128, 7–18
26. Graves, D. J. (1983) Methods Enzymol. 99, 268–278
27. Huang, C.-Y. F., Yuan, C.-J., Blumenthal, D. K., and Graves, D. J. (1995)
J. Biol. Chem. 270, 7183–7188
28. Sprang, S. R., Acharya, K. R., Goldsmith, E. J., Stuart, D. I., Varvill, K.,
Fletterick, R. J., Madsen, N. B., and Johnson, L. N. (1988) Nature 336,
215–221
29. Johnson, L. N. (1992) FASEB J. 6, 2274–2282
30. Newsholme, P., Angelos, K. L., and Walsh, D. A. (1992) J. Biol. Chem. 267,
810–818
31. Trewhella, J., Blumenthal, D. K., Rokop, S. E., and Seeger, P. A. (1990)
Biochemistry 29, 9316–9324
32. Sanchez, V. E., and Carlson, G. M. (1993) J. Biol. Chem. 268, 17889–17895
Bifunctional Regulatory Subdomains of Phosphorylase Kinase 22289
 by guest on February 1, 2018
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Maitrayee Dasgupta and Donald K. Blumenthal
ALSO AUTOINHIBITORY
THE TWO NONCONTIGUOUS CALMODULIN-BINDING SUBDOMAINS ARE 
-Subunit of Phosphorylase Kinase:γCharacterization of the Regulatory Domain of the 
doi: 10.1074/jbc.270.38.22283
1995, 270:22283-22289.J. Biol. Chem. 
  
 http://www.jbc.org/content/270/38/22283Access the most updated version of this article at 
 Alerts: 
  
 When a correction for this article is posted•  
 When this article is cited•  
 to choose from all of JBC's e-mail alertsClick here
  
 http://www.jbc.org/content/270/38/22283.full.html#ref-list-1
This article cites 30 references, 10 of which can be accessed free at
 by guest on February 1, 2018
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
